Una-Cidon, E;
Adeleke, S;
Masters, B;
Wood, V;
(2016)
Gefitinib.
In: Una-Cidon, E, (ed.)
The Easy Book of Cancer Pharmacology.
nova science publishers
Preview |
Text
Adeleke_Gefitinib formatted.pdf Download (426kB) | Preview |
Abstract
Gefitinib is a small molecule that specifically inhibits the tyrosine kinase (TK) activity of the epidermal growth factor receptor (EGFR) type 1 by interfering with the adenosine triphosphate (ATP) binding site. About 10% of patient with non-small cell lung cancer (NSCLC) in the US and about 35% in East Asia have EGFR mutations. [1] Hence gefitinib and the other EGFR inhibitor erlotinib are inevitably important in treatment of NSCLC, of the adenocarcinoma variant with the above mutation.
| Type: | Book chapter |
|---|---|
| Title: | Gefitinib |
| ISBN-13: | 9781634850384 |
| Open access status: | An open access version is available from UCL Discovery |
| Publisher version: | https://novapublishers.com/shop/the-easy-book-of-c... |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher's terms and conditions. |
| Keywords: | Targeted agent, personalised medicine, precision medicine |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine |
| URI: | https://discovery-pp.ucl.ac.uk/id/eprint/1503787 |
Archive Staff Only
 |
View Item |
